Multifunctional nanoplatform addresses three key barriers to effective TNBC immunotherapy

https://www.news-medical.net/news/20260821/Multifunctional-nanoplatform-addresses-three-key-barriers-to-effective-TNBC-immunotherapy.aspx Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15-20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with limited treatment options. Even immunotherapy - an approach that has transformed cancer treatment - benefits fewer than 20% of TNBC patients, largely because tumors contain large numbers of regulatory T cells (Tregs) that suppress the immune system and prevent it from effectively attacking cancer cells.